BioXcel Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTAI research report →
Companywww.bioxceltherapeutics.com
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
- CEO
- Vimal D. Mehta
- IPO
- 2018
- Employees
- 37
- HQ
- New Haven, CT, US
Price Chart
Valuation
- Market Cap
- $29.51M
- P/E
- -0.18
- P/S
- 43.40
- P/B
- -0.13
- EV/EBITDA
- -1.89
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 27.79%
- Op Margin
- -7395.00%
- Net Margin
- -11078.53%
- ROE
- 75.79%
- ROIC
- -3439.53%
Growth & Income
- Revenue
- $642.00K · -71.67%
- Net Income
- $-69,897,000 · -17.28%
- EPS
- $-5.73 · 75.63%
- Op Income
- $-50,267,000
- FCF YoY
- 20.01%
Performance & Tape
- 52W High
- $8.08
- 52W Low
- $1.01
- 50D MA
- $1.25
- 200D MA
- $2.16
- Beta
- 0.31
- Avg Volume
- 1.61M
Get TickerSpark's AI analysis on BTAI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Mehta Vimal | other | 18,000 |
| May 1, 26 | Mehta Vimal | other | 18,000 |
| May 1, 26 | Steinhart Richard I | other | 9,000 |
| May 1, 26 | Steinhart Richard I | other | 9,000 |
| May 1, 26 | Yocca Frank | other | 9,000 |
| May 1, 26 | Yocca Frank | other | 9,000 |
| May 1, 26 | Rodriguez Javier | other | 9,000 |
| May 1, 26 | Rodriguez Javier | other | 9,000 |
| Mar 15, 26 | Mehta Vimal | other | 219 |
| Mar 14, 26 | Mehta Vimal | other | 164 |
Our BTAI Coverage
We haven't published any research on BTAI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BTAI Report →